Retinoic acid receptor β2 hypermethylation: Implications for prostate cancer detection, prevention, and therapy

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 3935-3936

  Lotan, Reuben ^a   Lotan, Yair ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; DEMETHYLATING AGENT; EPIGALLOCATECHIN GALLATE; HISTONE DEACETYLASE INHIBITOR; MOLECULAR MARKER; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER THERAPY; CHEMOPROPHYLAXIS; DEMETHYLATION; DNA METHYLATION; EDITORIAL; EPIGENETICS; GENE HYPERMETHYLATION; GENE SILENCING; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUANTITATIVE ASSAY; QUANTITATIVE METHYLATION SPECIFIC POLYMERASE CHAIN REACTION;

DNA METHYLATION; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID;

EID: 3042580025     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0536     Document Type: Editorial

References (25)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Lee SW, Tomasetto C, Sager R. Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci USA 1991;88:2825-9.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
5. Virmani AK, Gazdar AF. Tumor suppressor genes in lung cancer. Methods Mol Biol 2003;222:97-115.
6. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003;170:2444-52.
7. Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003;106:382-7.
8. Zhang J, Liu L, Pfeifer GP. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene 2003;1-9.
9. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004;202:233-40.
10. Padar A, Sathyanarayana UG, Suzuki M, et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res 2003;9:4730-4.
11. Lotan Y, Xu XC, Shalev M, et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 2000;18:116-21.
12. Jerónimo C, Henrique R, Hoque OM, et al. Quantitative RARb2 hypermethylation: a promising prostate cancer marker. Clinical Cancer Res 2004;10:4010-14.
13. Harden SV, Sanderson H, Goodman SN, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst (Bethesda) 2003;95:1634-7.
14. Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 2004;63:414-8.
15. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55.
16. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (Bethesda) 1998;90:1621-5.
17. Moe-Behrens GH, Pandolfi PP. Targeting aberrant transcriptional repression in acute myeloid leukemia. Rev Clin Exp Hematol 2003;7:139-59.
18. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis-retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001;61:1477-85.
19. Sirchia SM, Ferguson AT, Sironi E, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000;19:1556-63.
20. Nakayama T, Watanabe M, Yamanaka M, et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Investig 2001;81:1049-57.
21. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-70.
22. Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 2004;10:1733-42.
23. Issa JP. Decitabine. Curr Opin Oncol 2003;15:446-51.
24. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst (Bethesda) 2003;95:1747-57.
25. Nelson WG, De Marzo AM, Deweese TL, et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann NY Acad Sci 2001;952:135-44.